Lung Transplantation
5
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
3
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
3
Early DiscoveryClinical DevelopmentMarket
On Market (3)
Approved therapies currently available
U
AMPHOTECApproved
amphotericin b
Unknown Companyinjection1996
U
AMPHOTERICIN BApproved
amphotericin b
Unknown CompanyLipid-based Polyene Antifungal [EPC]injection2025
Competitive Landscape
3 companies ranked by most advanced pipeline stage
XVIVOSweden - Mölndal
1 program1
Ex vivo lung perfusion with Steen Solution™Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
AstellasAmphotericin B
XVIVOEx vivo lung perfusion with Steen Solution™
One BiosciencesTrifecta-Lung cfDNA-MMDx Study
Clinical Trials (3)
Total enrollment: 48 patients across 3 trials
Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study
Start: Jan 2006Est. completion: Dec 200748 patients
Phase 3Completed
Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation
Start: Aug 2008Est. completion: Feb 2010
Phase 1Completed
Trifecta-Lung cfDNA-MMDx Study
Start: Nov 2023Est. completion: Dec 2027
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 48 patients
4 companies competing in this space